Chris Ogden
Chief Financial Officer, Cytomics Therapeutics
Replay available
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call
CytomX Therapeutics, Inc. (NASDAQ: CTMX) Q4 2025 earnings conference call, held 2026-03-16. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Shawn McCarthy
Chief Executive Officer & Chairman, Cytomics Therapeutics
Dr. Wayne Chiu
Chief Medical Officer, Cytomics Therapeutics
Edward Tenthoff
Analyst, Piper Sandler
Roger Song
Analyst, Jefferies
Matthew Beigler
Analyst, Opco
Michael Schmidt
Analyst, Guggenheim
Olivia Breyer
Analyst, Cantor Fitzgerald
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cytomx Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:02.213 Good morning, everyone. Thank you for standing by. 00:00:02.213 -- 00:00:07.659 Welcome to the Cytomics Therapeutics 2025 Financial Results and Faceta Phase 00:00:07.659 -- 00:00:12.303 1 Dose Expansion Data Call. Please be advised that today's conference is being recorded. 00:00:12.303 -- 00:00:16.808 I would now like to hand the conference call over to your host for today, Chris Ogden, 00:00:16.808 -- 00:00:21.451 Cytomics Chief Financial Officer. Please go ahead. 00:00:22.334 -- 00:00:26.238 Thank you. Good morning, and thank you for joining us. 00:00:26.238 -- 00:00:30.770 Before we begin, I would like to remind everyone that during this call, we'll be making 00:00:30.770 -- 00:00:32.713 forward-looking statements. 00:00:32.713 -- 00:00:36.598 Because forward-looking statements relate to the future, they're subject to inherent 00:00:36.598 -- 00:00:41.684 uncertainties and risks that are difficult to predict, and many of which are outside 00:00:41.684 -- 00:00:43.407 of our control. 00:00:43.407 -- 00:00:48.753 Important risks and uncertainties are set forth in our most recent public filings 00:00:48.753 -- 00:00:52.776 with the SEC at sec.gov. 00:00:52.799 -- 00:00:57.545 We undertake no obligation to update any forward-looking statements, whether as a result 00:00:57.545 -- 00:01:02.206 of new information future developments, or otherwise. 00:01:02.206 -- 00:01:08.173 Earlier today, we issued a press release that includes a summary of our 2025 financial 00:01:08.173 -- 00:01:11.915 results and progress at Cytomix. 00:01:12.018 -- 00:01:17.224 Additionally, this morning, we are excited to announce positive phase one dose expansion 00:01:17.224 -- 00:01:23.650 data for Varsetta N in patients with late-line colorectal cancer. 00...